A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer
Authors Michael H Nelson, Christian R Dolder
Published 15 September 2007 Volume 2007:3(4) Pages 665—673
Michael H Nelson1, Christian R Dolder1,2
1School of Pharmacy, Wingate University, Wingate, North Carolina, USA; 2Northeast Medical Center, Concord, North Carolina, USA
Abstract: Breast cancer remains a leading cause of disease and death among women throughout the world. Despite advances in drug therapy, development of novel and improved drugs for breast cancer continues to be of great interest. Lapatinib is a novel dual receptor tyrosine kinase inhibitor that is a selective and potent inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, both of which are growth promoting factors overexpressed in some breast cancers. Cell-based assays have proven lapatinib to be a potent inhibitor of ErbB-1 and ErbB-2 activation and breast cancer cell proliferation. In pharmacokinetic studies, lapatinib has shown mostly linear elimination kinetics over the daily dose range of 10–1600 mg and is metabolized by CYP3A4/5 and CYP2C19. Phase I, II, and III clinical trials involving lapatinib as monotherapy or in combination have shown promise for the treatment of advanced and metastatic breast cancer. Drug-drug interactions may occur secondary to concomitant administration of either CYP450 inhibitors or inducers. While lapatinib appear to be a promising addition to breast cancer therapy, several questions remain to be answered before its optimal role is elucidated.
Keywords: lapatinib, GW572016, breast cancer, tyrosine kinase inhibitor